Johnson & Johnson (JNJ) Financials
JNJ Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-03-31 | ? | ? |
| 2023-12-31 | 167.6 billion | 98.8 billion |
| 2023-09-30 | 166.1 billion | 94.8 billion |
| 2023-06-30 | 191.7 billion | 115.3 billion |
JNJ Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-03-31 | ? | ? |
| 2023-12-31 | 6.3 billion | 178.0 million |
| 2023-09-30 | 6.5 billion | 296.0 million |
| 2023-06-30 | 3.1 billion | 382.0 million |
JNJ Net Income
| Date | Net Income |
|---|---|
| 2024-03-31 | ? |
| 2023-12-31 | 4.1 billion |
| 2023-09-30 | 26.0 billion |
| 2023-06-30 | 5.1 billion |
JNJ Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-03-31 | - | - | - |
| 2023-12-31 | 22.9 billion | - | - |
| 2023-09-30 | 23.5 billion | 26.1 billion | - |
| 2023-06-30 | 28.5 billion | 33.9 billion | - |
JNJ Shares Outstanding
JNJ Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-03-31 | - | 3.5 billion | - | - |
| 2023-12-31 | 1.6 billion | 4.5 billion | 5.8 billion | - |
| 2023-09-30 | 967.0 million | 3.4 billion | 5.4 billion | - |
| 2023-06-30 | 1.1 billion | 3.8 billion | 6.7 billion | - |
JNJ Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-03-31 | 21.4 billion | 5.4 billion |
| 2023-12-31 | 21.4 billion | 7.0 billion |
| 2023-09-30 | 21.3 billion | 6.5 billion |
| 2023-06-30 | 25.5 billion | 8.2 billion |
JNJ
List: Champions
Price: $146.14
Dividend Yield: 3.35%
Forward Dividend Yield: 3.38%
Payout Ratio: 91.54%
Dividend Per Share: 4.96 USD
Earnings Per Share: 5.21 USD
P/E Ratio: 30.40
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 6.9 million
Ebitda: 2.9 billionMarket Capitalization: 356.4 billion
Average Dividend Frequency: 4
Years Paying Dividends: 63
DGR3: 5.62%
DGR5: 5.76%
DGR10: 5.98%
DGR20: 8.12%